Cibc World Markets Corp Purchases 1,709 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Cibc World Markets Corp boosted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 13.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 14,744 shares of the company’s stock after purchasing an additional 1,709 shares during the period. Cibc World Markets Corp’s holdings in IDEXX Laboratories were worth $6,096,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in IDXX. FSA Wealth Management LLC bought a new position in IDEXX Laboratories during the 3rd quarter valued at about $25,000. Rialto Wealth Management LLC bought a new position in IDEXX Laboratories during the 4th quarter valued at about $30,000. Retirement Wealth Solutions LLC bought a new position in IDEXX Laboratories during the 4th quarter valued at about $31,000. Kestra Investment Management LLC bought a new position in IDEXX Laboratories during the 4th quarter valued at about $38,000. Finally, Crews Bank & Trust acquired a new stake in IDEXX Laboratories in the 4th quarter valued at about $41,000. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Stock Up 0.6 %

IDEXX Laboratories stock opened at $422.15 on Thursday. The company’s 50 day simple moving average is $437.54 and its 200 day simple moving average is $445.70. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $548.88. The firm has a market capitalization of $34.33 billion, a price-to-earnings ratio of 39.56, a PEG ratio of 3.41 and a beta of 1.39. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95.

Insider Buying and Selling

In related news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares of the company’s stock, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by insiders.

Analysts Set New Price Targets

IDXX has been the subject of several research reports. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, March 15th. Barclays raised their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Piper Sandler raised their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Finally, Leerink Partners initiated coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective for the company. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.